Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced the presentation of data from ongoing clinical trials
evaluating the anti-tumor activity of pembrolizumab, the company’s
investigational anti-PD-1 antibody, at the European Society of Medical
Oncology (ESMO) 2014 in Madrid, Spain, September 26 – 30.
for - Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Company’s Investigational Anti-PD-1 Antibody, at ESMO 2014 investment picks